NCT05992363 Tandem Polyurethane Stents Compared to Single Silicone Stent for Malignant Ureteral Obstruction
| NCT ID | NCT05992363 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Rabin Medical Center |
| Condition | Hydronephrosis; Obstruction, Ureter |
| Study Type | INTERVENTIONAL |
| Enrollment | 106 participants |
| Start Date | 2023-12-20 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 106 participants in total. It began in 2023-12-20 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Malignant ureteral obstruction (MUO) is an extrinsic ureteral obstruction caused by malignant diseases. This study aim to compare tandem 6 Fr Percuflex™ stents and single large-caliber 8Fr silicone stent in patients with MUO. The primary endpoint is stent failure rate. The secondary endpoints are patient comfort, quality of life and overall survival.
Eligibility Criteria
Inclusion Criteria: * patient with malignant ureteral obstruction Exclusion Criteria: * ureteral obstruction of other causes * Language comprehension or other limitation in giving informed consent
Frequently Asked Questions
Who can join the NCT05992363 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hydronephrosis; Obstruction, Ureter. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05992363 currently recruiting?
Yes, NCT05992363 is actively recruiting participants. Visit ClinicalTrials.gov or contact Rabin Medical Center to inquire about joining.
Where is the NCT05992363 trial being conducted?
This trial is being conducted at Petah Tikva, Israel, Ramat Gan, Israel.
Who is sponsoring the NCT05992363 clinical trial?
NCT05992363 is sponsored by Rabin Medical Center. The trial plans to enroll 106 participants.